Improving antihypertensive therapy in patients with diabetic nephropathy

Southern Medical Journal
Christian W Mende

Abstract

Nearly all patients with diabetic nephropathy have comorbid hypertension, which greatly elevates the risk for cardiovascular events. As patients are surviving longer, their risk of progressing to end-stage renal disease is increasing, particularly in patients with type 2 diabetes. Prevention of cardiovascular and renal events in this population requires diligent efforts to control blood pressure, serum glucose, and serum lipids. Improving antihypertensive therapy in patients with diabetic nephropathy relies on the following unified strategies: reducing blood pressure to <130/80 mm Hg, prescribing an agent that blocks the renin-angiotensin system, and designing an antihypertensive regimen that both reduces albuminuria and provides cardiovascular protection. A majority of patients will require three or more antihypertensive agents to achieve these objectives. Appropriate antihypertensive therapy in patients with diabetic nephropathy delays progression of renal disease and leads to substantial cost savings.

References

Jan 4, 1996·The New England Journal of Medicine·M J KlagJ Stamler
Sep 8, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G L BakrisJ Sowers
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Sep 22, 2001·The New England Journal of Medicine·T H Hostetter
Jan 5, 2002·The American Journal of Geriatric Cardiology·Warren J Elliott, Henry R Black
May 22, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN CDC Diabetes Cost-effectiveness Group
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Mar 8, 2003·Archives of Internal Medicine·Janice G DouglasUNKNOWN Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
Mar 13, 2003·Kidney International·William F KeaneUNKNOWN RENAAL Study Investigators
Apr 23, 2003·Hypertension·Masahiko TozawaShuichi Takishita
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jul 16, 2003·Archives of Internal Medicine·George L BakrisUNKNOWN RENAAL Study Group
Dec 25, 2003·Diabetes Care·Carlos Arauz-PachecoUNKNOWN American Diabetes Association
Dec 25, 2003·Diabetes Care·Mark E MolitchUNKNOWN American Diabetes Association
Jan 15, 2004·PharmacoEconomics·Jonathan D RippinStephen C Bain
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Mar 17, 2004·Journal of Diabetes and Its Complications·Adam GordoisAlan Oglesby
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Keith Norris, Charles Vaughn
Aug 17, 2004·American Heart Journal·Peter A McCulloughRobert M Califf
Nov 2, 2004·The New England Journal of Medicine·Anthony H BarnettUNKNOWN Diabetics Exposed to Telmisartan and Enalapril Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.